Generic Name: maraviroc

Pronunciation: sell-ZEN-tree

Abbreviation: MVC

Other Market Name: Celsentri

Drug Class: Entry Inhibitors

Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Not part of a recommended or alternative treatment regimen for antiretroviral-naive people living with HIV, according to the U.S. Department of Health and Human Services (DHHS) Antiretroviral Guidelines for Adults and Adolescents. Generally reserved for treatment-experienced people living with HIV. Visit for the full DHHS guidelines.

General Info

Selzentry is an HIV medication. It is in a category of HIV medicines called entry inhibitors. Selzentry was approved by the U.S. Food and Drug Administration for use by people living with HIV in August 2007.

Selzentry is approved for treatment-experienced people who have HIV strains that are resistant to multiple antiretroviral drugs and for people with drug-sensitive HIV strains, such as those starting antiretroviral therapy for the first time.

Selzentry must be used in combination with other HIV drugs.


Adult Dose: One 150mg, 300mg, or 600mg tablet, twice a day, depending on other medications used.

Pediatric Dose: Selzenty can be prescribed for children two years of age and older weighing at least 22 pounds. Available formulations include an oral solution containing 20 mg/mL maraviroc, as well as 25 mg and 75 mg tablets.

Dosing Info: Take with or without food.

Side Effects

Liver toxicity is one of the more serious side effects associated with Selzentry. An allergic reaction may happen before liver problems occur. If you develop a rash, yellowing of the skin or eyes, dark urine, vomiting, or abdominal pain after starting Selzentry, contact your health care provider immediately.

Another possible side effect is low blood pressure when standing up (postural hypotension). This can cause dizziness and fainting.

In clinical trials, more cardiovascular events, including heart attacks, were seen in patients receiving Selzentry as compared to placebo. In turn, the manufacturer and the FDA are recommending that the drug be used with caution in patients at increased risk for cardiovascular events.

Because Selzentry blocks the CCR5 coreceptor located on some immune system cells, there is a theoretical risk of developing infections and cancers. However, rates of infections and cancer were no higher among patients receiving Selzentry, versus those receiving placebo, in year-long clinical trials.

The most common side effects of Selzentry include colds, cough, fever, rash, and dizziness.

Drug Interactions

While Selzentry does not generally have a major effect on the levels of other HIV and non-HIV drugs in the body, other medications can significantly affect Selzentry levels in the blood.

Your health care provider may need to carefully select or adjust your Selzentry dose when taking any of the following HIV drugs: Prezista (darunavir), Kaletra (lopinavir/ritonavir), Norvir (ritonavir), Reyataz (atazanavir), Invirase (saquinavir), Viracept (nelfinavir), Crixivan (indinavir), Lexiva (fosamprenavir), Intelence (etravirine), Vitekta (elvitegravir), Rescriptor (delavirdine), or Sustiva or Atripla (efavirenz).

Selzentry dose adjustments may also be required when taking any of the following non-HIV drugs: Tegretol (carbamazepine), Dilantin (phenytoin), Nizoral (ketonconazle), Sporanox (itraconazole), Biaxin (clarithromycin), nefazodone, Ketek (telithromycin), Rifadin/Rifater (rifampin), phenobarbital, Victrelis (boceprevir).

Other drug interactions are possible. Consult the Selzentry package insert for details:

Other Info

Before taking this medication, tell your doctor if you have kidney disease, liver disease (including hepatitis B), or a history of depression/suicidal thoughts. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: February 4, 2017